Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Epstein, M. Amin, V. Reuter, F. Mostofi, F. Algaba, W. Allsbrook, A. Ayala, M. Becich, A. Beltrán, L. Boccon-Gibod, D. Bostwick, C. Busch, C. Davis, J. Eble, C. Foster, M. Furusato, D. Grignon, P. Humphrey, E. Ishak, S. Johansson, E. Jones, L. Koss, H. Levin, W. Murphy, R. Petersen, A. Renshaw, J. Ro, J. Ross, I. Sesterhenn, J. Srigley, S. Suzigan, J. Tomaszewski, P. Troncoso, L. True, M. Weiss, T. Wheeler, R. Young (1998)
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladderThe American Journal of Surgical Pathology, 22
J. Epstein, M. Amin, V. Reuter, F. Mostofi (1998)
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.The American journal of surgical pathology, 22 12
P. Clark, N. Agarwal, M. Biagioli, M. Eisenberger, R. Greenberg, H. Herr, B. Inman, D. Kuban, T. Kuzel, S. Lele, J. Michalski, L. Pagliaro, S. Pal, A. Patterson, E. Plimack, K. Pohar, M. Porter, J. Richie, W. Sexton, W. Shipley, E. Small, P. Spiess, D. Trump, Geoffrey Wile, T. Wilson, M. Dwyer, M. Ho (2013)
Bladder cancer.Journal of the National Comprehensive Cancer Network : JNCCN, 11 4
M. Hall, Sam Chang, G. Dalbagni, R. Pruthi, J. Seigne, E. Skinner, J. Wolf, P. Schellhammer (2007)
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.The Journal of urology, 178 6
Liang Cheng, J. Cheville, R. Neumann, D. Bostwick (2000)
Flat intraepithelial lesions of the urinary bladderCancer, 88
P. Harnden, I. Eardley, A. Joyce, J. Southgate (1996)
Cytokeratin 20 as an objective marker of urothelial dysplasia.British journal of urology, 78 6
Ok Mangrud, Rune Waalen, E. Gudlaugsson, I. Dalen, I. Tasdemir, E. Janssen, J. Baak (2014)
Reproducibility and Prognostic Value of WHO1973 and WHO2004 Grading Systems in TaT1 Urothelial Carcinoma of the Urinary BladderPLoS ONE, 9
Tadeusz Majewski, Sangkyou Lee, Joon Jeong, D. Yoon, A. Kram, Mi-Sook Kim, T. Tuziak, J. Bondaruk, Sooyong Lee, W. Park, Kuang Tang, W. Chung, Lanlan Shen, Saira Ahmed, D. Johnston, H. Grossman, C. Dinney, J. Zhou, R. Harris, C. Snyder, S. Filipek, S. Narod, P. Watson, H. Lynch, A. Gazdar, M. Bar‐eli, Xifeng Wu, D. McConkey, K. Baggerly, J. Issa, W. Benedict, S. Scherer, B. Czerniak (2008)
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategyLaboratory Investigation, 88
Á. Sarkis, G. Dalbagni, C. Cordon-Cardo, J. Melamed, Zuo‐Feng Zhang, J. Sheinfeld, W. Fair, H. Herr, V. Reuter (1994)
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.The Journal of urology, 152 2 Pt 1
Clark (2013)
Bladder cancerJ Natl Compr Canc Netw, 11
Jennifer Southgate, P. Harnden, L. Trejdosiewicz (1999)
Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications.Histology and histopathology, 14 2
A. Hartmann, G. Schlake, D. Zaak, E. Hungerhuber, A. Hofstetter, F. Hofstaedter, R. Knuechel (2002)
Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.Cancer research, 62 3
the urinary bladder correlates with disease progression
M. Requena, J. Alvarez-Kindelan, A. Blanca (2007)
Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review.Analytical and quantitative cytology and histology, 29 6
J. McKenney, S. Desai, C. Cohen, M. Amin (2001)
Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic Urothelium: An Analysis of Cytokeratin 20, p53, and CD44 AntigensThe American Journal of Surgical Pathology, 25
Wei Sun, Ping Zhang, G. Herrera (2002)
p53 Protein and Ki-67 Overexpression in Urothelial Dysplasia of BladderApplied Immunohistochemistry & Molecular Morphology, 10
M. Aron, D. Luthringer, J. McKenney, D. Hansel, Danielle Westfall, R. Parakh, S. Mohanty, Bonnie Balzer, M. Amin (2013)
Utility of a Triple Antibody Cocktail Intraurothelial Neoplasm-3 (IUN-3-CK20/CD44s/p53) and &agr;-Methylacyl-CoA Racemase (AMACR) in the Distinction of Urothelial Carcinoma In Situ (CIS) and Reactive Urothelial AtypiaThe American Journal of Surgical Pathology, 37
S. Murata, M. Iseki, M. Kinjo, O. Matsuzaki, A. Moriuchi, H. Ohtani, T. Sakurai, T. Satake, T. Tsuzuki (2010)
Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder.American journal of clinical pathology, 134 6
C. Mallofré, M. Castillo, Vanesa Morente, M. Solé (2003)
Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial DysplasiaModern Pathology, 16
Liang Cheng, J. Cheville, R. Neumann, B. Leibovich, K. Egan, Bruce Spotts, D. Bostwick (1999)
Survival of patients with carcinoma in situ of the urinary bladderCancer, 85
Hui Yin, Qun He, Tingting Li, A. Leong (2006)
Cytokeratin 20 and Ki-67 to Distinguish Carcinoma In Situ From Flat Non-neoplastic UrotheliumApplied Immunohistochemistry & Molecular Morphology, 14
N. Nese, Ruta Gupta, M. Bui, M. Amin (2009)
Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.Journal of the National Comprehensive Cancer Network : JNCCN, 7 1
C. Steidl, R. Simon, H. Bürger, C. Brinkschmidt, L. Hertle, W. Böcker, H. Terpe (2002)
Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urotheliumThe Journal of Pathology, 198
Soini (1993)
p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progressionBr J Cancer, 68
L. Kunju, Cheryl Lee, J. Montie, R. Shah (2005)
Utility of cytokeratin 20 and Ki‐67 as markers of urothelial dysplasiaPathology International, 55
R. Zuk, H. Rogers, J. Martin, S. Baithun (1988)
Clinicopathological importance of primary dysplasia of bladder.Journal of Clinical Pathology, 41
B. Isfoss, B. Majak, C. Busch, G. Braathen (2011)
Diagnosis of intraurothelial neoplasia. Interobserver variation and the value of individual histopathologic attributes.Analytical and quantitative cytology and histology, 33 2
D. McConkey, Sangkyou Lee, W. Choi, M. Tran, Tadeusz Majewski, Sooyong Lee, A. Siefker-Radtke, C. Dinney, B. Czerniak (2010)
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.Urologic oncology, 28 4
E. Oliva, Nathanael Pinheiro, N. Heney, D. Kaufman, W. Shipley, Carol Gurski, B. Spicer, Gladell Paner, A. Gown, M. Amin (2013)
Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.Human pathology, 44 5
Background:Distinguishing urothelial carcinoma in situ (CIS) from other flat lesions of the urinary bladder with cytologic atypia is critically important for the management of patients with bladder neoplasia. However, there is high interpathologist variability in making these distinctions.Objective:The aim of this study is to assess interobserver agreement between general and specialized genitourinary pathologists, and to compare these diagnoses with those rendered after an immunohistochemical panel is performed. We hypothesized that addition of a set of immunohistochemical stains would reduce the number of cases classified within intermediate categories of atypia of uncertain significance and low-grade dysplasia.Design:Two genitourinary pathologists independently assessed haematoxylin and eosin (H&E)–stained sections of 127 bladder biopsies from each of the 4 International Society of Urological Pathology/World Health Organization categories of flat lesions diagnosed by general pathologists. A subset of biopsies from 49 patients was reassessed after staining with a 3-antibody panel (CD44, CK20, and p53) and the results were correlated with patient follow-up.Results:Based on these immunohistochemistry (IHC) stains, 26 cases (53.1%) were recategorized. Of most clinical importance, 5 of 27 cases (18.5%) originally diagnosed as either atypia of uncertain significance or low-grade dysplasia were recategorized as CIS, and recurrent disease was identified on subsequent biopsies. None of the 10 cases diagnosed as CIS based on H&E stains were recategorized.Conclusions:This triad of IHC stains can improve the precision of pathologic diagnosis of histologically atypical urothelial lesions of flat bladder mucosa. We recommend that pathologists apply this set of IHC stains to such lesions they find problematic based on H&E stains.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.